[A23-103] Sacubitril/valsartan (heart failure, children and adolescents) – Addendum to Commission A23-56
Last updated 07.12.2023
Project no.:
A23-103
Commission:
Commission awarded on 24.10.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Heart and circulation
Children and adolescents aged 1 year or older with symptomatic chronic heart failure with left ventricular systolic dysfunction
Unchanged after addendum: Added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://dx.doi.org/10.60584/A23-103
| Project no. | Title | Status |
|---|---|---|
| A23-56 | Sacubitril/valsartan (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2023-12-07 A G-BA decision was published.